Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 25, 2025

Drilling Programs Define New Zones as Gold Still Targets $5,000

View original at globenewswire.com
Drilling Programs Define New Zones as Gold Still Targets $5,000 Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, British Columbia, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The high-grade results exceeded expectations and demonstrate exceptional potential of flagship project which ranks as one of highest-grade undeveloped open pittable gold deposits in Canada

    80% confidence

  • Lake Victoria Gold is executing dual-track strategy: developing Imwelo toward first production within 12 months of construction while maintaining optionality through Barrick's fully funded exploration

    80% confidence

  • The Q3 results from Barrick highlight a systematic and technically strong approach to unlocking the Tembo geology

    80% confidence

  • Core hole LADD031 demonstrates that the BIF is still thick and well mineralized at 570m depth toward the projected northwest edge of Adumbi deposit

    80% confidence

  • Gold will reach $5,055 per ounce by late 2026 driven by sustained central bank accumulation

    80% confidence

  • Gold will reach $5,055 per ounce by late 2026 driven by sustained central bank accumulation

    80% confidence

  • Q3 2025 was highly successful with construction of Stage 3 Plant under budget, multiple financial records, and company is in strongest financial position in history

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Drilling Programs Define New Zones as Gold Still Targets $5,000 — Source | Via News | Via News